Drug Approval | August 17, 2021
Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site
The approval allows it to market its products in the country
The approval allows it to market its products in the country
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Subscribe To Our Newsletter & Stay Updated
